Contact Information: Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 or Diane Meegan Investor Relations 212-330-8512 .
Daxor Corporation Announces Queen's Medical Center of Honolulu, HI Purchases Second Blood Volume Analyzer
| Source: Daxor Corp.
NEW YORK, NY--(Marketwire - October 26, 2007) - Daxor Corporation (AMEX : DXR ), a medical
instrumentation and biotechnology company, today announced receipt of a
signed purchase agreement from the Queen's Medical Center in Honolulu,
Hawaii for its second Blood Volume Analyzer BVA-100.
Dr. Mihae Yu, Professor of Surgery and Program Director of Surgical
Critical Care, said that, "I have found blood volume measurements to be
extremely useful in guiding both fluid and red cell replacement.
Approximately one third of the time our clinical criteria, combining
physical exam, clinical information, laboratory data and chest x-ray, may
be misleading in terms of the intravascular volume status. Traditional
methods of guessing intravascular volume status is particularly difficult
in edematous patients post shock resuscitation. Also, we may be over as
well as under-transfusing blood cells when using hematocrit as a guide,
since hematocrit values may not reflect red cell volume. We need to study
blood volume measurements further and determine its impact on patient
outcomes. However, I have found the BVA-100 to be clinically useful as to
warrant a second unit."
An October 17, 2007 Wall Street Journal article titled "Hospitals Combat an
Insidious Complication" discusses how many hospitals are trying new
strategies to combat permanent loss of memory and cognition in critical
care patients. Inadequate oxygen delivery to the brain due to unrealized
blood loss (blood volume) is a recognized cause of this kind of permanent
brain damage. Previously reported clinical studies from Queen's Medical
Center demonstrate how a measured intravascular blood volume provides a
more accurate guide to recognizing and treating critical care patients who
require a blood transfusion. Queen's Medical Center is one of the leading
hospitals in the United States that routinely utilizes the BVA-100 for
their critical care patients.
Daxor's goal is to help improve patient outcomes and reduce the cost of
care through the diagnostic tool of an intravascular blood volume
measurement. Daxor Corporation manufactures and markets the BVA-100, a
semi-automated, FDA approved Blood Volume Analyzer. The BVA-100 is used in
conjunction with Volumex, a single use diagnostic kit. The BVA-100 measures
intravascular blood volume to within a 98% accuracy. More information
about the BVA-100 and Volumex can be found at www.daxor.com.